Codeine-related deaths: The role of pharmacogenetics and drug interactions

Forensic Science International

Volumn 239, Issue , 2014, Pages 50-56

  Lam, Jessica ^a,b   Woodall, Karen L ^c   Solbeck, Patricia ^c   Ross, Colin J D ^d,e   Carleton, Bruce C ^d,e   Hayden, Michael R ^d,e   Koren, Gideon ^a,b,f   Madadi, Parvaz ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Ministry of Community Safety and Correctional Services Centre of Forensic Sciences   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^f WESTERN UNIVERSITY   (Canada)

Author keywords

ABCB1; Codeine; CYP2D6; Drug interactions; Pharmacogenetics; Post mortem

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CLOBAZAM; CLONAZEPAM; CODEINE; CYTOCHROME P450 2D6; DIAZEPAM; DIPHENHYDRAMINE; FENTANYL; FLUOXETINE; GLUCURONOSYLTRANSFERASE 2B7; HYDROCODONE; HYDROMORPHONE; LORAZEPAM; MORPHINE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; OXAZEPAM; OXYCODONE; PAROXETINE; PETHIDINE; SERTRALINE; ZOPICLONE; CENTRAL DEPRESSANT AGENT; CYTOCHROME P450 2D6 INHIBITOR; NARCOTIC AGENT;

ABCB1 GENE; ADULT; ARTICLE; AUTOPSY; BLOOD ANALYSIS; CANADA; COMT GENE; CYPD26 GENE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG METABOLISM; DRUG MISUSE; DRUG POTENCY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPRM1 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; SUICIDE; TOXICITY TESTING; UGT2B7 GENE; BLOOD; DRUG INTERACTION; FORENSIC GENETICS; FORENSIC TOXICOLOGY; GENETIC POLYMORPHISM; GENETICS; LIQUID CHROMATOGRAPHY; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

ADULT; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHROMATOGRAPHY, LIQUID; CODEINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; DRUG INTERACTIONS; FEMALE; FORENSIC GENETICS; FORENSIC TOXICOLOGY; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NARCOTICS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TANDEM MASS SPECTROMETRY;

EID: 84919764752     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.03.018     Document Type: Article

References (46)

1. DAWN Drug Abuse Warning Network 2011: National estimates of drug-related emergency department visits 2013.
2. CDC, Center for Disease Control and Prevention CDC grand rounds: prescription drug overdose - a U.S. epidemic. MMWR Morb. Mortal. Wkly Rep. 2012, 61:10-13.
3. Dhalla I.A., Mandani M.M., Sivilotti M.L., Kopp A., Qureshi O., Juurlink D.N. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009, 181:891-896.
4. Leander J.D., Lucot J.B. Toxic interactions of stimulant, narcotics and narcotics antagonist. Res. Commun. Chem. Pathol. Pharmacol. 1977, 17:255-264.
5. Haberman P.W., Noble J.A., Dufour M.C. Alcohol use in combination with cocaine, heroin and methadone by medical examiner cases. J. Stud. Alcohol 1995, 56:344-357.
6. Ruttenber A.J., Kalter H.D., Santinga P. The role of ethanol abuse in the etiology of heroin-related death. J. Forensic Sci. 1990, 35:891-900.
7. Gasche Y., Daali Y., Fathi M., Chiappe A., Cottini S., Dayer P., Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 2004, 351:2827-2831.
8. Desmeules J., Gascon M.P., Dayer P., Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol. 1991, 41:23-26.
9. Thorn C.F., Klein T.E., Altman R.B. Codeine and morphine pathway. Pharmacogenet. Genom. 2009, 19:556-558.
10. Koren G., Cairns J., Chitayat D., Gaedigk A., Leeder S.J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006, 368:704.
11. Madadi P., Ross C.J., Hayden M.R., Carleton B.C., Gaedigk A., Leeder J.S., Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 2009, 85:31-35.
12. Eissing T., Lippert J., Willmann S. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol. Diagn. Ther. 2012, 16:43-53.
13. Kelly L.E., Reider M., van den Anker J., Malkin B., Ross C., Neely M.N., Carleton B., Hayden M.R., Madadi P., Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics 2012, 129:e1343-e1347.
14. Sistonen J., Madadi P., Ross C.J., Yazdanpanah M., Lee J.W., Landsmeer M.L., Nauta M., Carleton B.C., Koren G., Hayden M.R. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin. Pharmacol. Ther. 2012, 91:692-699.
15. Madadi P., Hildebrandt D., Lauwers A.E., Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS ONE 2013, 8. (Epub Apr 5).
16. Cozza K.L., Armstrong S.C., Oesterheld J.R. Concise guide to drug interaction principles for medical practice: cytochrome P450s, UGTs, P-glycoproteins. Am. Psychiatr. Assoc 2003.
17. FDA, U.S.Food and Drug Administration Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers 2011.
18. Hemeryck A., Belpaire F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 2002, 3:13-37.
19. Oh J., Kimchi-Sarfaty C., Kim I., Sherman A., Ambudkar S., Gottesman M. Functional characterization of SNP and haplotype of human MDR1 gene using a vaccinia virus expression system. Clin. Pharmacol. Ther. 2005, 77:P24.
20. Coffman B.L., Rios G.R., King C.D., Tephly T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 1997, 25:1-4.
21. Duguay Y., Baar C., Skorpen F., Guillemetter C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 2004, 75:223-233.
22. Zhang Y., Wang D., Johnson A.D., Papp A.C., Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 2005, 280:32618-32624.
23. Lee P.J., Delaney P., Keogh J., Sleeman D., Shorten G.D. Catecholamine O-methyltransferase polymorphisms are associated with postoperative pain intensity. Clin. J. Pain 2011, 27:93-101.
24. Rakvag T.T., Klepstad P., Baar C., Kvam T.M., Dale O., Kaasa S., Krokan H.E., Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005, 116:73-78.
25. Reyes-Gibby C.C., Shate S., Rakvag T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., Klepstand P. Exploring joint effects of genes and clinical efficacy of morphine in cancer pain: OPRM1 and COMT gene. Pain 2007, 130:25-30.
26. Ahlets S.J., Elens L.L., van Gulik L., van Schall R.H., van Dongen E.P., Bruins P., Tibboel D., Knibbs C.A. The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery. Br. J. Clin. Pharmacol. 2013, 75:1506-1515.
27. Rakvag T.T., Ross J.R., Sato H., Skarpen F., Kaasa S., Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain 2008, 4:64.
28. Gaedigk A., Simon S.D., Pearce R.E., Bradford L.D., Kennedy M.J., Leeder J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 2008, 83:234-242.
29. Fernandes L.C., Kilicarslan T., Kaplan H.L., Tyndale R.F., Sellers E.M., Romach M.K. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. J. Clin. Psychopharmacol. 2002, 22:326-329.
30. Sindrup S.H., Hoffman U., Asmussen J., Mikus G., Brosen K., Nielsen F., Ingwersen S.H., Broen Christensen C. Impact of quinidine on plasma and CSF concentration codeine and morphine after codeine intake. Eur. J. Clin. Pharmacol. 1996, 49:503-509.
31. Pergolizzi J.V., Labhsetwar S.A., Puenpatom A., Joo S., Be-Joseph R.H., Summers K.H. Prevalence of exposure to potential CYP450 pharmacokinetics drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract. 2011, 11:230-239.
32. Rattan A.K., Sribanditmongkol P. Effect of morphine-induced catalepsy, lethality, and analgesia by a benzodiazepine receptor agonist midazolam in the rat. Pharmacol. Biochem. Behav. 1994, 48:357-361.
33. Garty M., Ben-Zvi Z., Hurwitz A. Opioid effect on lidocaine disposition and toxicity in mice. J. Pharmacol. Exp. Ther. 1985, 234:391-394.
34. Puschel K. Drug-related death - an update. Forensic Sci. Int. 1993, 62:121-128.
35. Darke S., Sunjic S., Zador D., Prolov T. A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. Drug Alcohol Depend. 1997, 47:45-53.
36. Gossop M., Stewart D., Treacy S., Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2007, 97:39-47.
37. Cone E.J., Fant R.V., Rohay J.M., Caplan Y.H., Ballina M., Reder R.F., Haddox J.D. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J. Anal. Toxicol. 2004, 28:616-624.
38. Vandel S., Bertschy G., Vandel B., Allers G., Volmat R. Nonlinear kinetics of nortriptyline in every day practice. Eur. J. Clin. Pharmacol. 1990, 39:97-98.
39. Jerling M., Alvan G. Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring. Eur. J. Clin. Pharmacol. 1994, 46:67-70.
40. Gerostamoulos J., Drummer O.H. Postmortem redistribution of morphine and its metabolites. J. Forensic Sci. 2000, 45:843-845.
41. Trolliver S.S., Hearn W.L., Furton K.G. Evaluating the relationship between postmortem and antemortem morphine and codeine concentrations in whole blood. J. Anal. Toxicol. 2010, 34:491-497.
42. Logan B.K., Smirnow D. Postmortem distribution and redistribution of morphine in man. J. Forensic Sci. 1996, 41:221-229.
43. Crandall C.S., Kerrigan S., Blau R.L., Lavalley J., Zumwalt R., McKinney P.E. The influence of site on collection on postmortem morphine concentrations in heroin overdose victims. J. Forensic Sci. 2006, 51:413-420.
44. Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 2007, 81:429-444.
45. Bourasset F., Schermann J.M. Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-glucuronide. Life Sci. 2006, 78:2302-2314.
46. Xie R., Hammarlund-Udenaes M., de Boer A.G. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br. J. Pharmacol. 1999, 128:563-568.